Roth Capital downgraded Alexza Pharmaceuticals ALXA from Buy to Neutral.
The target price for Alexza Pharmaceuticals has been lowered from $10.00 to $5.50.
Alexza Pharmaceuticals shares have declined 6.54% over the past 52 weeks, while the S&P 500 index has gained 12.49% in the same period.
Alexza Pharmaceuticals' shares gained 2.97% to close at $4.86 yesterday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in